Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03696212
Title Grapiprant (ARY-007) and Pembrolizumab in Patients With Advanced or Metastatic Post-PD-1/L1 NSCLC Adenocarcinoma
Recruitment Terminated
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors Arrys Therapeutics
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA

Facility Status City State Zip Country Details
Stanford University Medical Center Stanford California 94305 United States Details
Barbara Ann Karmanos Cancer Institute Detroit Michigan 48201 United States Details
START Midwest Grand Rapids Michigan 49546 United States Details
University of Pennsylvania Abramson Cancer Center Philadelphia Pennsylvania 19104 United States Details
Fox Chase Cancer Center Philadelphia Pennsylvania 19111 United States Details
Virginia Cancer Specialists Fairfax Virginia 22031 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field